336 related articles for article (PubMed ID: 17290029)
1. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04).
Wilcox R; Bousser MG; Betteridge DJ; Schernthaner G; Pirags V; Kupfer S; Dormandy J;
Stroke; 2007 Mar; 38(3):865-73. PubMed ID: 17290029
[TBL] [Abstract][Full Text] [Related]
2. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.
Erdmann E; Dormandy JA; Charbonnel B; Massi-Benedetti M; Moules IK; Skene AM;
J Am Coll Cardiol; 2007 May; 49(17):1772-80. PubMed ID: 17466227
[TBL] [Abstract][Full Text] [Related]
3. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
Wilcox R; Kupfer S; Erdmann E;
Am Heart J; 2008 Apr; 155(4):712-7. PubMed ID: 18371481
[TBL] [Abstract][Full Text] [Related]
4. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
Dormandy JA; Charbonnel B; Eckland DJ; Erdmann E; Massi-Benedetti M; Moules IK; Skene AM; Tan MH; Lefèbvre PJ; Murray GD; Standl E; Wilcox RG; Wilhelmsen L; Betteridge J; Birkeland K; Golay A; Heine RJ; Korányi L; Laakso M; Mokán M; Norkus A; Pirags V; Podar T; Scheen A; Scherbaum W; Schernthaner G; Schmitz O; Skrha J; Smith U; Taton J;
Lancet; 2005 Oct; 366(9493):1279-89. PubMed ID: 16214598
[TBL] [Abstract][Full Text] [Related]
5. [Evidences demonstrating the effects of anti-atherosclerotic actions of pioglitazone--special emphasis on PROactive Study and PERISCOPE Study].
Kawamori R
Nihon Rinsho; 2010 Feb; 68(2):235-41. PubMed ID: 20158090
[TBL] [Abstract][Full Text] [Related]
6. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients.
Charbonnel B; Dormandy J; Erdmann E; Massi-Benedetti M; Skene A;
Diabetes Care; 2004 Jul; 27(7):1647-53. PubMed ID: 15220241
[TBL] [Abstract][Full Text] [Related]
7. Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes.
Erdmann E; Harding S; Lam H; Perez A
Diabetes Obes Metab; 2016 Mar; 18(3):266-73. PubMed ID: 26592506
[TBL] [Abstract][Full Text] [Related]
8. Organ protection in the secondary prevention of type 2 diabetes.
Schernthaner G
Drugs Today (Barc); 2006 Dec; 42 Suppl C():17-23. PubMed ID: 17245477
[TBL] [Abstract][Full Text] [Related]
9. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).
Erdmann E; Charbonnel B; Wilcox RG; Skene AM; Massi-Benedetti M; Yates J; Tan M; Spanheimer R; Standl E; Dormandy JA;
Diabetes Care; 2007 Nov; 30(11):2773-8. PubMed ID: 17666462
[TBL] [Abstract][Full Text] [Related]
10. Observational follow-up of the PROactive study: a 6-year update.
Erdmann E; Song E; Spanheimer R; van Troostenburg de Bruyn AR; Perez A
Diabetes Obes Metab; 2014 Jan; 16(1):63-74. PubMed ID: 23859428
[TBL] [Abstract][Full Text] [Related]
11. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.
Valentine WJ; Bottomley JM; Palmer AJ; Brändle M; Foos V; Williams R; Dormandy JA; Yates J; Tan MH; Massi-Benedetti M;
Diabet Med; 2007 Sep; 24(9):982-1002. PubMed ID: 17593245
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular risk and cardiometabolic protection: role of glitazones.
Petrazzi L; Grassi D; Polidoro L; D'Aurelio A; Croce G; Properzi G; Tiberti S; Desideri G; Ferri C
J Nephrol; 2008; 21(6):826-35. PubMed ID: 19034866
[TBL] [Abstract][Full Text] [Related]
13. Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population.
Doehner W; Erdmann E; Cairns R; Clark AL; Dormandy JA; Ferrannini E; Anker SD
Int J Cardiol; 2012 Dec; 162(1):20-6. PubMed ID: 22037349
[TBL] [Abstract][Full Text] [Related]
14. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.
Lincoff AM; Wolski K; Nicholls SJ; Nissen SE
JAMA; 2007 Sep; 298(10):1180-8. PubMed ID: 17848652
[TBL] [Abstract][Full Text] [Related]
15. Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus.
Young LH; Viscoli CM; Curtis JP; Inzucchi SE; Schwartz GG; Lovejoy AM; Furie KL; Gorman MJ; Conwit R; Abbott JD; Jacoby DL; Kolansky DM; Pfau SE; Ling FS; Kernan WN;
Circulation; 2017 May; 135(20):1882-1893. PubMed ID: 28246237
[TBL] [Abstract][Full Text] [Related]
16. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.
Lincoff AM; Tardif JC; Schwartz GG; Nicholls SJ; Rydén L; Neal B; Malmberg K; Wedel H; Buse JB; Henry RR; Weichert A; Cannata R; Svensson A; Volz D; Grobbee DE;
JAMA; 2014 Apr; 311(15):1515-25. PubMed ID: 24682069
[TBL] [Abstract][Full Text] [Related]
17. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial.
Vaccaro O; Masulli M; Bonora E; Del Prato S; Giorda CB; Maggioni AP; Mocarelli P; Nicolucci A; Rivellese AA; Squatrito S; Riccardi G;
Nutr Metab Cardiovasc Dis; 2012 Nov; 22(11):997-1006. PubMed ID: 23063367
[TBL] [Abstract][Full Text] [Related]
18. Impact of peripheral arterial disease in patients with diabetes--results from PROactive (PROactive 11).
Dormandy JA; Betteridge DJ; Schernthaner G; Pirags V; Norgren L;
Atherosclerosis; 2009 Jan; 202(1):272-81. PubMed ID: 18538774
[TBL] [Abstract][Full Text] [Related]
19. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
[TBL] [Abstract][Full Text] [Related]
20. CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone.
Betteridge DJ
Fundam Clin Pharmacol; 2009 Dec; 23(6):675-9. PubMed ID: 19744248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
